B. Olsson

发表

Food Increases the Bioavailability of Tolterodine but Not Effective Exposure

B. Olsson, N. Brynne, C. Johansson, 2001, Journal of clinical pharmacology.

rhBSSL Improves Growth and LCPUFA Absorption in Preterm Infants Fed Formula or Pasteurized Breast Milk

A. Lapillonne, V. Carnielli, C. Casper, 2014, Journal of pediatric gastroenterology and nutrition.

Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers

B. Olsson, D. Lindqvist, P. Dalén, 2018, European Journal of Clinical Pharmacology.

Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria

J. Jarvis, A. Zatkova, L. Ranganath, 2020, Journal of inherited metabolic disease.

Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine

B. Olsson, J. Gabrielsson, P. Bolme, 2004, European Journal of Clinical Pharmacology.

Human pharmacokinetics of iohexol. A new nonionic contrast medium.

B. Olsson, E. Andrew, K. Sveen, 1983, Investigative radiology.

Multiple Dose Pharmacokinetics of a New Once Daily Extended Release Tolterodine Formulation Versus Immediate Release Tolterodine

B. Olsson, J. Szamosi, 2001, Clinical pharmacokinetics.

Food Does Not Influence the Pharmacokinetics of a New Extended Release Formulation of Tolterodine for Once Daily Treatment of Patients with Overactive Bladder

B. Olsson, J. Szamosi, 2001, Clinical pharmacokinetics.

The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel.

B. Olsson, B. Landgren, 2001, Clinical therapeutics.

Absorption of iohexol from cerebrospinal fluid to blood: pharmacokinetics in humans

B. Olsson, O. Eldevik, T. A. Grønnerød, 2004, Neuroradiology.

Clinical trial of intravenous dextro-alprenolol in cardiac arrhythmias

G. Nyberg, B. Olsson, L. Orö, 1971, European Journal of Clinical Pharmacology.

Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on ‘black bone disease’ in Italy

Ludevit Kadasi, Jan Radvanszky, Andrea Zatkova, 2015, European Journal of Human Genetics.

Absorption of quinidine from an enteric-coated preparation

B. Olsson, L. Storstein, J. Amlie, 1979, European Journal of Clinical Pharmacology.

Pharmacokinetic and pharmacodynamic interactions between palifermin and heparin

William Smith, B. Olsson, Bing‐Bing Yang, 2015, Journal of clinical pharmacology.

Absolute bioavailability of quinidine in two sustained release preparations

B. Olsson, L. Storstein, J. Amlie, 1979, European Journal of Clinical Pharmacology.

Safety, Pharmacokinetics, and Efficacy of Palifermin in Children and Adolescents with Acute Leukemias Undergoing Myeloablative Therapy and Allogeneic Hematopoietic Stem Cell Transplantation: A Pediatric Blood and Marrow Transplant Consortium Trial.

B. Olsson, T. Moore, V. Aquino, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: a pharmacokinetic study.

S Rosberg, B. Olsson, K. Albertsson-Wikland, 1993, The Journal of clinical endocrinology and metabolism.

Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria afte

Andrea Zatkova, Annalisa Santucci, Daniela Braconi, 2014, Annals of the rheumatic diseases.

Homogentisate 1,2-dioxygenase (HGD) gene variants, their analysis and genotype–phenotype correlations in the largest cohort of patients with AKU

J. Královičová, D. Ascher, L. Ranganath, 2019, European Journal of Human Genetics.

Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial.

J. Jarvis, L. Ranganath, B. Olsson, 2020, The lancet. Diabetes & endocrinology.

Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria.

L. Ranganath, B. Olsson, A. Milan, 2015, JIMD reports.

A gamma scintigraphic study of the absorption of morphine from controlled-release tablets

B. Olsson, G. Ragnarsson, Z. Wagner, 1995 .

Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers

B. Olsson, D. Lindqvist, P. Dalén, 2018, European Journal of Clinical Pharmacology.

Excretion of noscapine in human breast milk

B. Olsson, C. Marcus, P. Bolme, 2004, European Journal of Clinical Pharmacology.

Effects of a protein‐restricted diet on body weight and serum tyrosine concentrations in patients with alkaptonuria

B. Olsson, A. Milan, R. Imrich, 2021, JIMD reports.

once daily nitisinone on 24-hour urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment

Martina, J. Jarvis, L. Ranganath, 2015 .

Open-Label Single-Sequence Crossover Study Evaluating Pharmacokinetics, Efficacy, and Safety of Once-Daily Dosing of Nitisinone in Patients with Hereditary Tyrosinemia Type 1

B. Olsson, N. Guffon, A. Bröijersén, 2017, JIMD reports.

Doxycycline carrageenate — an improved formulation providing more reliable absorption and plasma concentrations at high gastric pH than doxycycline monohydrate

A. Grahnén, B. Olsson, G. Johansson, 2004, European Journal of Clinical Pharmacology.

Homogentisate 1,2-dioxygenase (HGD) gene variants, their analysis and genotype–phenotype correlations in the largest cohort of patients with AKU

J. Královičová, D. Ascher, L. Ranganath, 2019, European Journal of Human Genetics.